Firefly Neuroscience (NASDAQ:AIFF) Upgraded at Wall Street Zen
by Doug Wharley · The Cerbat GemWall Street Zen upgraded shares of Firefly Neuroscience (NASDAQ:AIFF – Free Report) to a hold rating in a report published on Saturday.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.
Check Out Our Latest Analysis on AIFF
Firefly Neuroscience Stock Up 4.0%
Shares of NASDAQ AIFF opened at $1.83 on Friday. Firefly Neuroscience has a twelve month low of $0.62 and a twelve month high of $4.51. The stock’s 50 day moving average price is $1.54 and its 200-day moving average price is $1.55. The company has a market capitalization of $27.07 million, a PE ratio of -1.02 and a beta of 0.58.
Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.41 million for the quarter. Firefly Neuroscience had a negative net margin of 1,740.98% and a negative return on equity of 229.99%.
Institutional Trading of Firefly Neuroscience
Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after buying an additional 401,085 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Firefly Neuroscience in the fourth quarter worth about $53,000. Geode Capital Management LLC lifted its holdings in shares of Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after buying an additional 58,067 shares in the last quarter. Finally, Savvy Advisors Inc. bought a new position in shares of Firefly Neuroscience in the third quarter valued at approximately $63,000. Hedge funds and other institutional investors own 4.96% of the company’s stock.
About Firefly Neuroscience
Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.
The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.